-
A Breakthrough in Cancer Care: Jaypirca Receives Expanded FDA Approval
NYSE: $LLY A New Chapter for Patients with CLL and SLL The landscape of treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has shifted significantly. Eli Lilly and Company recently announced that the U.S. Food and Drug Administration (FDA) has granted expanded approval for Jaypirca (pirtobrutinib). This milestone marks an important advancement…
-
A New Milestone in Blood Cancer Treatment: FDA Expands Approval for Jaypirca
NYSE: $LLY A New Therapeutic Option for CLL/SLL Patients The landscape of blood cancer treatment has taken a significant step forward. The U.S. Food and Drug Administration (FDA) has granted expanded approval for Jaypirca (pirtobrutinib), marking it as the first and only non-covalent BTK inhibitor available for patients with previously untreated chronic lymphocytic leukemia (CLL)…